MedPal AI (MPAL) Trading update summary

Pharmacy operations performance

• Processed 33,433 prescription orders in December 2025, generating turnover of approximately £325,000 at an average item value of £9.72.

• Achieved 16% month-on-month growth in prescription volumes compared to November 2025, despite a shortened trading month.

• Growth driven by successful NHS Distance Selling Pharmacy contract integration and increased uptake of private weight loss services.

Market developments and strategic positioning

• FDA approved the first oral GLP-1 (Wegovy pill) for weight loss, enabling a once-daily pill alternative to injections.

• Clinical trials showed up to 16.6% weight loss in adherent patients over 64 weeks, comparable to injectable forms.

• Oral format expected to expand the addressable market by removing barriers like needle aversion and refrigeration.

• AI-powered MedPal.clinic is positioned to capitalize on the expanded market with scalable triage and prescription fulfillment.

Technology and partnerships

• Operates a 24/7 AI-powered automated pharmacy distribution center with robotic dispensing and rapid delivery.

• Core app aggregates data from over 100 wearables and health apps, offering personalized lifestyle guidance.

• Partnership with Epassi UK Limited provides exclusive, zero-cost app access to over 11 million employees at major firms.

• Plans to expand via B2B licensing to healthcare providers, businesses, and insurers for wellness programs.